Physician profile
Ashlin Charboneau
NPI 1114571536
$7,632.27
in general payments reported to CMS, 2019-2025
41 companies · $976 in 2025
The $976 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $545 · 2022: $805 · 2023: $2,414 · 2024: $2,891 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,899 · Consulting Fee: $2,500 · Travel and Lodging: $699 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,898.79 |
| Consulting Fee | $2,500.00 |
| Travel and Lodging | $698.98 |
| Education | $184.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,865.37 | 2022-2025 | |
| Incyte Corporation | $641.23 | 2021-2025 | Jakafi, Pemazyre, Monjuvi |
| Astellas Pharma US INC | $306.33 | 2022-2025 | Xospata, Cresemba, Xtandi |
| Jazz Pharmaceuticals INC. | $289.50 | 2021-2023 | |
| Sobi, INC | $223.56 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $214.89 | 2022-2025 | Calquence, Imfinzi |
| Janssen Biotech, INC. | $200.34 | 2022-2024 | Erleada, Rybrevant, Akeega |
| Novartis Pharmaceuticals Corporation | $178.16 | 2024-2025 | |
| Genzyme Corporation | $172.03 | 2022-2024 | |
| Amgen INC. | $162.03 | 2023-2024 | Blincyto, Lumakras, Kyprolis |
| Takeda Pharmaceuticals U.S.A., INC. | $127.44 | 2022-2024 | Ninlaro, Iclusig |
| Lilly USA, LLC | $107.32 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Eisai INC. | $104.97 | 2023-2024 | |
| Glaxosmithkline, LLC. | $100.09 | 2025 | Ojjaara |
| Tersera Therapeutics LLC | $82.35 | 2022-2024 | Zoladex |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashlin Charboneau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.